Filing Flows

Filing Flows › Companies › Rapport Therapeutics › Cash flow

Rapport Therapeutics cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$41.6M in Q3 2026 · −$121M over twelve months

Operating cash flow−$41.6M
Free cash flow−$41.6M

Analysis

In Q3 2026, Rapport Therapeutics generated −$41.6M of operating cash flow. That is $24.0M less than in Q3 2025 (−$17.6M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$121M; the largest uses were operating cash flow ($121M), other investing ($59.4M), other financing ($853K); besides operations, cash came from shares issued ($4.8M); the cash balance fell by $177M.

Operating cash flow was −$41.6M against net income of −$40.2M. The largest differences: stock-based pay +$7.6M, accrued liabilities −$6.9M, payables −$1.1M.

Free cash flow

Rapport Therapeutics: free cash flow by quarterRapport Therapeutics: free cash flow by quarter−$14.7MQ4 2024−$20.5MQ1 2025−$25.1MQ2 2025−$17.6MQ3 2025−$24.9MQ4 2025−$13.1MQ1 2026−$41.5MQ2 2026−$41.6MQ3 2026
Operating cash flow less capital spending.
Rapport Therapeutics: operating cash flow against capital spendingRapport Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$14.4M$226KQ4 2024−$20.2M$291KQ1 2025−$25.1M$22KQ2 2025−$17.5M$134KQ3 2025−$24.7M$169KQ4 2025−$13.1M$86KQ1 2026−$41.5M$78KQ2 2026−$41.6M$0Q3 2026
Latest (Q3 2026): Operating cash flow −$41.6M, Capital spending $0.

Capital allocation, year by year

Rapport Therapeutics: where the cash came from (up) and went (down), by fiscal yearRapport Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2023: Operating cash flow −$27.2MFY2023: Shares issued $54KFY2023: Capital spending −$1.6M$54KFY2023FY2024: Operating cash flow −$64.8MFY2024: Shares issued $7KFY2024: Capital spending −$2.4M$7KFY2024FY2025: Operating cash flow −$87.5MFY2025: Shares issued $1.3MFY2025: Capital spending −$616K$1.3MFY2025
Over these 3 years operating cash flow totalled −$179M; the largest uses were operating cash flow ($179M) and capital spending ($4.7M). Cash-flow statements as filed.

Where the cash came from and went

Rapport Therapeutics: sources (+) and uses (−) of cash, Q3 2026Rapport Therapeutics: sources (+) and uses (−) of cash, Q3 2026Other investing$50.9MOperating cash flow−$41.6MCash drawn (+) / kept (−)−$11.1MShares issued$1.7MAsset & business sales$208KOther financing$1K
Rapport Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Rapport Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Cash drawn (+) / kept (−)$177MOperating cash flow−$121MOther investing−$59.4MShares issued$4.8MOther financing−$853KCapital spending−$333K

From profit to cash

Rapport Therapeutics: net income to operating cash flow, Q3 2026Rapport Therapeutics: net income to operating cash flow, Q3 2026Net income−$40.2MDepreciation & amortization$198KStock-based pay$7.6MReceivables$122KPayables−$1.1MAccrued liabilities−$6.9MPrepaid and other assets−$855KOperating cash flow−$41.6M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$41.6M—$1.7M−$11.1M−$41.6M
Q2 2026−$41.5M−$78K$1.6M$14.4M−$41.5M
Q1 2026−$13.1M−$86K$809K−$25.4M−$13.1M
Q4 2025−$24.7M−$169K$706K$199M−$24.9M
Q3 2025−$17.5M−$134K$636K−$196M−$17.6M
Q2 2025−$25.1M−$22K—$2.5M−$25.1M
Q1 2025−$20.2M−$291K$6K−$799K−$20.5M
Q4 2024−$14.4M−$226K—−$17.5M−$14.7M

Rapport Therapeutics: income statement and cash flow

Rapport Therapeutics, Q1 2026: revenue $20.0M, operating margin -121.1%. The chart follows the revenue to costs, profit and cash.

Rapport Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.